KOBV Portal

Hits per page

hit 1 - 1 | 1 hit

Select All Export

Online Resource

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Gigoux, Mathieu ; Holmström, Morten O. ; Zappasodi, Roberta ; [et al.]

American Association for the Advancement of Science (AAAS) ; 2022

In: Science Translational Medicine Vol. 14, No. 649 ( 2022-06-15)

add to watchlist on the watchlist

Details

In: Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 649 ( 2022-06-15)

Abstract: Myeloproliferative neoplasms (MPNs) that have frameshift mutations in calreticulin (CALR) rarely have T cells that target this neoantigen. Gigoux et al . investigated the lack of these T cells by examining class I major histocompatiblity complex (MHC-I) allele frequencies in these patients. They saw a skewing of these alleles and thus developed a heteroclitic peptide vaccine to activate T cells against these tumors. They saw a response in patient samples ex vivo and in mice to immunization with this peptide, which represents a promising treatment for patients with this disease.

Type of Medium: Online Resource

ISSN: 1946-6234 , 1946-6242

URL: Article

DOI: 10.1126/scitranslmed.aba4380

Language: English

Publisher: American Association for the Advancement of Science (AAAS)

Publication Date: 2022